| 3.46 0.09 (2.67%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.63 | 1-year : | 5.19 |
| Resists | First : | 3.96 | Second : | 4.44 |
| Pivot price | 3.47  |
|||
| Supports | First : | 3.19 | Second : | 2.65 |
| MAs | MA(5) : | 3.37 |
MA(20) : | 3.52 |
| MA(100) : | 3.58 |
MA(250) : | 5.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28 |
D(3) : | 22.7 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 9.93 | Low : | 2.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALVO ] has closed above bottom band by 47.4%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.47 - 3.49 | 3.49 - 3.5 |
| Low: | 3.25 - 3.27 | 3.27 - 3.29 |
| Close: | 3.43 - 3.46 | 3.46 - 3.49 |
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Fri, 17 Jul 2026
ALVO Stock Price Prediction 2025-2026 | Alvotech Forecast - 24/7 Wall St.
Wed, 15 Jul 2026
Alvotech (ALVO) Could Be 76% Below Fair Value On New $75 Million Debt Facility - simplywall.st
Tue, 14 Jul 2026
Alvotech (NASDAQ:ALVO) Shares Down 5.5% - Here's What Happened - MarketBeat
Mon, 13 Jul 2026
Alvotech (ALVO) Barclays 27th Annual Global Healthcare Conference 2025 Summary - Quartr
Fri, 10 Jul 2026
Alvotech (ALVO) Q3 2025 earnings summary - Quartr
Sun, 05 Jul 2026
Alvotech (ALVO) Secured $240 Million In New Capital, Is The Stock Cheap? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 338 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 54.5 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,930 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.9 |
| Profit Margin | -14.4 % |
| Operating Margin | 9.1 % |
| Return on Assets (ttm) | 3.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -20.3 % |
| Gross Profit (p.s.) | 1.02 |
| Sales Per Share | 1.66 |
| EBITDA (p.s.) | 0.3 |
| Qtrly Earnings Growth | -99 % |
| Operating Cash Flow | -123 (M) |
| Levered Free Cash Flow | -93 (M) |
| PE Ratio | -11.94 |
| PEG Ratio | 0 |
| Price to Book value | -3.85 |
| Price to Sales | 2.08 |
| Price to Cash Flow | -9.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|